References
- Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res 2005;36:197-209
- Bell DS. Importance of postprandial glucose control. South Med J 2001;94:804-9
- Coates PA, Ollerton RL, Owens DR, et al. A glimpse of ‘natural history’ of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis. Diabetes Res Clin Pract 1994;26:177-87
- Polonsky KS, Sturis J, Bell GI. Non-insulin dependent diabetes mellitus – a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996;334:777-83
- Polonsky KS, Given BD, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin dependent diabetes mellitus. N Engl J Med 1998;318:1231-9
- Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
- UK Prospective Diabetes Study Group. Intensive blood-glucose control with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
- International Diabetes Federation. Guidelines task force, Brussels, 2005
- Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13 (Suppl 1):1-68
- Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: analogue or human?. Diabetes Obes Metab 2007;9:630-9
- Sharma SK, Al-Mustafa M, Oh SJ, et al. Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: results from the PRESENT study. Curr Med Res Opin 2008;24:645-52
- Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes. Diabetes Care 2005;28:260-5
- Kann PH, Wascher T, Zackova V, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006;114:527-32
- Ligthelm RJ, Borzi V, Gumprecht J, et al. Importance of observational studies in clinical practice. Clin Ther 2007;29:1284-92
- Concato J. Observational versus experimental studies: what's the evidence for a hierarchy?. NeuroRx 2004;1:341-7
- Valensi P, Benroubi M, Borzi V, et al., on behalf of the IMPROVE Study Group Expert Panel. The IMPROVE study – a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract 2008;62:1809-19
- Brod M, Skovlund SE, Wittrup-Jensen KU. Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience. Qual Life Res 2006;15:481-91
- Bodmer M, Meier C, Krähenbühl S, et al. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care 2008;31:2086-91
- Bebakar WMW, Chow CC, Kadir KA, et al. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:724-32
- Boehm BO, Vaz JA, Brøndsted L, et al. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med 2004;15:496-502
- Valensi P, Benroubi M, Borzi V, et al, IMPROVE Study Group Expert Panel. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Int J Clin Pract 2009 Mar;63:522-31